- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.06. | Dicot Pharma AB: Dicot Pharma announces final outcome in the oversubscribed rights issue and carries out directed share issues | 413 | GlobeNewswire (Europe) | Uppsala, Sweden, June 9, 2026. Dicot Pharma AB announced on June 4, 2026, the preliminary outcome of the rights issue of units of approximately SEK 210 million (the "Rights Issue"). Today, the company... ► Artikel lesen | |
| 04.06. | Dicot Pharma AB: Dicot Pharma announces preliminary outcome in oversubscribed rights issue | 320 | GlobeNewswire (Europe) | Uppsala, Sweden, June 4, 2026. Dicot Pharma AB ("Dicot Pharma" or the "Company") today announces the preliminary outcome of the rights issue of units of approximately SEK 210 million (the "Rights Issue")... ► Artikel lesen | |
| 03.06. | Decision by the Disciplinary Committee regarding Dicot Pharma AB | 142 | GlobeNewswire | Stockholm, June 3, 2026 The Disciplinary Committee of Nasdaq Stockholm has found that Dicot Pharma AB (the "Company") has not breached the rules of Nasdaq Stockholm (the "Rulebook") and has therefore... ► Artikel lesen | |
| DICOT PHARMA Aktie jetzt für 0€ handeln | |||||
| 01.06. | Dicot Pharma AB: Dicot Pharma receives patent approval in Japan for LIB-01 | 128 | GlobeNewswire (Europe) | Uppsala, Sweden, June 1, 2026. Dicot Pharma has been granted a new patent in Japan for the active substance in LIB-01. The patent strengthens the intellectual property of the company's drug candidate... ► Artikel lesen | |
| 29.05. | Dicot Pharma AB: Dicot Pharma announces the final subscription date for units in the ongoing rights issue | 249 | GlobeNewswire (Europe) | Uppsala, Sweden, May 29, 2026. Thursday, June 4, 2026, is the final day for subscription in Dicot Pharma AB's ("Dicot Pharma" or "the Company") ongoing rights issue of units, consisting of shares and... ► Artikel lesen | |
| 27.05. | Dicot Pharma AB: Dicot Pharma receives indications of interest for approx. SEK 15.6 million from existing shareholders in the ongoing rights issue | 284 | GlobeNewswire (Europe) | Uppsala, Sweden, May 27, 2026. Dicot Pharma AB ("Dicot Pharma" or the "Company") has now received indications of interest from certain major shareholders totaling approximately SEK 15.6 million in the... ► Artikel lesen | |
| 20.05. | Dicot Pharma AB: Dicot Pharma completes tablet manufacturing ahead of phase 2b clinical study | 273 | GlobeNewswire (Europe) | Uppsala, Sweden, May 20, 2026. Dicot Pharma AB announces that the company has successfully completed manufacturing of the drug candidate LIB-01 as a tablet for the planned phase 2b study, which is intended... ► Artikel lesen | |
| 19.05. | Dicot Pharma AB: Dicot Pharma publishes prospectus in connection with the forthcoming rights issue | 268 | GlobeNewswire (Europe) | Dicot Pharma AB ("Dicot Pharma" or the "Company") today, on May 19, 2026, publishes an EU Follow-on Prospectus (the "Prospectus") in connection with the rights issue of units, consisting of shares and... ► Artikel lesen | |
| 08.05. | Dicot Pharma AB: Dicot Pharma has resolved on an 80% guaranteed rights issue of approximately SEK 210 million | 830 | GlobeNewswire (Europe) | Uppsala, Sweden, May 8, 2026. The Board of Directors of Dicot Pharma AB ("Dicot Pharma" or the "Company") announced on April 28, 2026 its intention to resolve on a rights issue with preferential rights... ► Artikel lesen | |
| 06.05. | Dicot Pharma AB: Report from the Annual General Meeting of Dicot Pharma | 252 | GlobeNewswire (Europe) | Uppsala, Sweden, May 6, 2026. Dicot Pharma AB held its Annual General Meeting today in Uppsala where the following decisions were made.
Annual report and resultsThe meeting adopted the income statements... ► Artikel lesen | |
| 30.04. | Dicot Pharma AB: Dicot Pharma presents interim report Q1 2026 and invites to a webcast | 238 | GlobeNewswire (Europe) | Uppsala, Sweden, April 30, 2026. Dicot Pharma AB publishes its interim report for the first quarter of 2026. The report is available as an attached document and on www.dicotpharma.com. The company will... ► Artikel lesen | |
| 28.04. | Dicot Pharma AB: Dicot Pharma intends to carry out an 80% already secured rights issue of SEK 210 million | 612 | GlobeNewswire (Europe) | Uppsala, Sweden, April 28, 2026. The Board of Directors of Dicot Pharma AB ("Dicot Pharma" or the "Company") intends to resolve on a rights issue of units, consisting of shares and warrants, corresponding... ► Artikel lesen | |
| 12.03. | Dicot Pharma AB: Dicot Pharma initiates tablet manufacturing ahead of phase 2b clinical study | 303 | GlobeNewswire (Europe) | Uppsala, Sweden, March 12, 2026. Dicot Pharma AB announces that the company has successfully completed the development of LIB-01 as a tablet and initiated manufacturing of tablets ahead of the upcoming... ► Artikel lesen | |
| 18.12.25 | Dicot Pharma AB: Dicot Pharma signs agreement with CRO ahead of phase 2b study with LIB-01 | 513 | GlobeNewswire (Europe) | Uppsala, Sweden, December 18, 2025. Dicot Pharma AB has signed an agreement with a global contract research organization (CRO) to prepare for the planned phase 2b clinical study of the drug candidate... ► Artikel lesen | |
| 23.10.25 | Dicot Pharma AB: Dicot Pharma Announces Positive Results from its Phase 2a Study | 511 | GlobeNewswire (Europe) | Uppsala, Sweden October 23, 2025. Today, Dicot Pharma announces positive topline results from its phase 2a study of LIB-01 for the treatment of erectile dysfunction. The outcomes demonstrated clinically... ► Artikel lesen | |
| 27.08.25 | Dicot Pharma AB: Dicot Pharma included in global stock index | 439 | GlobeNewswire (Europe) | Uppsala, Sweden, August 27, 2025. As of today, the Swedish, erectile dysfunction drug developer Dicot Pharma has been incorporated into the MSCI Global Micro Cap Index, managed by MSCI, the world's... ► Artikel lesen | |
| 20.08.25 | Dicot Pharma AB: Dicot Pharma's Phase 2a study completed - results within three months | 409 | GlobeNewswire (Europe) | Uppsala, Sweden, August 20, 2025. Today, potency drug developer Dicot Pharma announces that the clinical part of its phase 2a study has been completed, as the final participant now has completed the... ► Artikel lesen | |
| 12.08.25 | Dicot Pharma AB: Dicot Pharma presents interim report Q2 2025 | 422 | GlobeNewswire (Europe) | Uppsala, Sweden, August 12, 2025. Dicot Pharma AB publishes its interim report for the second quarter of 2025. The report is available as an attached document and on www.dicotpharma.com. The company's... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CHRISTINA LAKE CANNABIS | 0,020 | 0,00 % | Christina Lake Cannabis Corp: Christina Lake investor Milia acquires 5.03M shares | ||
| PSYCHED WELLNESS | 0,008 | 0,00 % | Psyched Wellness Ltd: Psyched Wellness CEO Stevens, director Stodulski resign | ||
| GREENRISE GLOBAL BRANDS | 0,005 | -100,00 % | CSE Bulletin: Suspensions - Adastra Holdings Ltd., CAT Strategic Metals Corporation, Greenrise Global Brands Inc., StickIt Technologies Inc. | Le 12 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101... ► Artikel lesen | |
| NUMINUS WELLNESS | 0,027 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 23.04.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.04.2026ISIN NameAU000000BMG3 BMG... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,033 | 0,00 % | Betterlife Pharma Inc (2): Betterlife Pharma extends warrants by one year | ||
| MEDIPHARM LABS | 0,040 | -11,11 % | MediPharm Labs Corp.: MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders | TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based... ► Artikel lesen | |
| ADDEX THERAPEUTICS | 0,048 | 0,00 % | Addex Therapeutics: Addex Convenes Annual General Meeting 2026 | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 5, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| PROMINO NUTRITIONAL SCIENCES | 0,019 | 0,00 % | Promino Nutritional Sciences, Inc.: Promino Expands U.S. NCAA Athlete Platform with Multi-Sport NIL Agreement with Every True Tiger | Promino expands its U.S. NCAA NIL platform with Every True Tiger, the third-party marketing arm of the Missouri Tigers, and select student-athletes across leading sports, including football, basketball... ► Artikel lesen | |
| ARGENT BIOPHARMA | 0,014 | 0,00 % | ARGENT BIOPHARMA LIMITED: Long Term Aquiol Licensing and Supply Agreement | ||
| CANNABIST COMPANY | 0,020 | 0,00 % | XFRA VW5: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCANNABIST CO.HLDG.INC... ► Artikel lesen | |
| IANTHUS CAPITAL | 0,001 | 0,00 % | iAnthus Capital Holdings, Inc.: iAnthus Reports Fiscal First Quarter 2026 Financial Results | NEW YORK and TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- iAnthus Capital Holdings, Inc. ("iAnthus" or the "Company") (CSE: IAN, OTCID: ITHUF), which owns, operates, and partners with regulated cannabis... ► Artikel lesen | |
| CENTR BRANDS | 0,001 | 0,00 % | Centr Brands Corp (2): Centr Brands closes $100,000 debenture financing | ||
| RESTART LIFE SCIENCES | 0,051 | 0,00 % | Restart Life Sciences Corp.: Restart Life Advances AI-Driven E-Commerce Strategy to Scale Online Sales Growth for Holy Crap Foods | Vancouver, British Columbia--(Newsfile Corp. - June 18, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that... ► Artikel lesen | |
| AYR WELLNESS | 0,050 | 0,00 % | Ayr Wellness Inc.: AYR Wellness Announces Closing of Exit Facility and Related Transactions | MIAMI, April 10, 2026 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) ("AYR" or the "Company"), a leading vertically integrated U.S. multi-state cannabis operator, announces the initial... ► Artikel lesen | |
| GREY MATTERS HEALTH | 0,310 | 0,00 % | Grey Matters Health Inc.: Grey Matters Announces Increase to Private Placement Financing to $1.25 Million and Closing of Offering | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 18, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the "Company" or... ► Artikel lesen |
DICOT PHARMA AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,012 (-44,73 %) liegt der Kurs bei 0,015 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DICOT PHARMA AB finden Sie auf Wallstreet Online.